Cadila Healthcare can begin a new bull run on technical levels......analysis is also backed by news of Virafin(an antiviral produced by Cadila Healthcare) being given emergency approval for treatment of moderate COVID-19 patients.
Volume has also increased drastically.
Cadila has also given closing above a trendline which was previously acting as resistance for the price to move up.
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.